Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1246 to 1260 of 2183 results for guidelines

  1. Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)

    Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making

    Evidence summary
    Published
    24 May 2016

  2. Upadacitinib for treating moderate rheumatoid arthritis (TA744)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderate active rheumatoid arthritis in adults.

    Technology appraisal guidance
    Published
    10 November 2021
    View recommendations

    Sections for TA744

  3. Terms and conditions

    clinical guidelines on the management and treatment of particular conditions and its ongoing development of such recommendations and...

  4. Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections (AMR1)

    Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.

    Antimicrobial resistance guidance
    Published
    17 August 2022
    View recommendations

    Sections for AMR1

  5. Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (AMR2)

    Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.

    Antimicrobial resistance guidance
    Published
    17 August 2022
    View recommendations

    Sections for AMR2

  6. Biopatch for venous or arterial catheter sites (MIB117)

    NICE has developed a medtech innovation briefing (MIB) on Biopatch for venous or arterial catheter sites .

    Medtech innovation briefing
    Published
    9 August 2017

  7. Paige Prostate for prostate cancer (MIB280)

    NICE has developed a medtech innovation briefing (MIB) on Paige Prostate for prostate cancer .

    Medtech innovation briefing
    Published
    30 November 2021

  8. Botulinum toxin type A:- What is the clinical and cost effectiveness of botulinum toxin type A when used routinely or according to clinical need in children and young people who are at Gross Motor Function Classification System (GMFCS) level I, II or III?

    Any explanatory notes(if applicable) Why this is important:- The Guideline Development Group's (GDG's) recommendation to consider...

    Research recommendation
    Published
    9 June 2015

  9. Healthy start vitamins: special report on cost effectiveness (ECD5)

    This document describes a special report on the cost effectiveness of moving the Healthy Start vitamin programme from the current targeted offering to a universal offering

  10. Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

    Evidence-based recommendations on abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel) and tocilizumab (RoActemra) for treating juvenile idiopathic arthritis in children, young people and adults.

    Technology appraisal guidance
    Published
    16 December 2015
    View recommendations

    Sections for TA373

  11. Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)

    Evidence-based recommendations on treosulfan (Trecondi) with fludarabine for conditioning treatment before allogeneic haematopoietic stem cell transplant for malignant diseases in people for whom a reduced intensity regimen would be suitable.

    Technology appraisal guidance
    Published
    5 August 2020
    View recommendations

    Sections for TA640

  12. Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)

    Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.

    Technology appraisal guidance
    Published
    6 December 2023
    View recommendations

    Sections for TA935

  13. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on treating complications from mesh used for pelvic organ prolapse – Options for women referred to specialist centres

    for decision aids (see www.nice.org.uk/sdm) and are based on the NICE guideline on urinary incontinence and pelvic organ prolapse in...

  14. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on treating complications from mesh used for stress urinary incontinence – Options for women referred to specialist centres

    for decision aids (see www.nice.org.uk/sdm) and are based on the NICE guideline on urinary incontinence and pelvic organ prolapse in...

  15. Holistic assessment in the community:- What is the clinical and cost effectiveness of a community holistic assessment and intervention for people living with high levels of multimorbidity?

    the UK and were not aimed at all adults living with multimorbidity. The guideline committee believed that there was some evidence that...

    Research recommendation
    Published
    18 October 2016